

About the Notice:	Risk Evaluation and Mitigation Strategy (REMS) for buprenorphine-containing transmucosal products. Buprenorphine is an opioid and like other opioids, has the potential for being abused and misused. Abuse poses a risk of overdose or death.
Products(s) numbers/models that are affected:	Buprenorphine-containing transmucosal products
URL Link(s) to Manufacturer Notice/Web Site:	REMS has been implemented as a FDA requirement to ensure the benefits outweigh the potential risks. https://www.btodrems.com
Actions to be taken by customer/Patient:	The dispensing pharmacist will supply a Medication Guide with each prescription. The guide can also be obtained online by https://www.btodrems.com or calling 1-855-223-3922.